Changing Hearts and Minds: Improving Outcomes in Cancer Treatment-Related Cardiotoxicity.

Author(s): Shelburne N,  Simonds NI,  Adhikari B,  Alley M,  Desvigne-Nickens P,  Dimond E,  Filipski K,  Gallicchio L,  Minasian L

Journal: Curr Oncol Rep

Date: 2019 Jan 30

Major Program(s) or Research Group(s): BGCRG, OD

PubMed ID: 30701318

PMC ID: not available

Abstract: PURPOSE OF REVIEW: Cardiovascular effects from cancer treatment remains a leading cause of treatment-associated morbidity and mortality among cancer survivors. The National Cancer Institute and National Heart, Lung, and Blood Institute convened a Workshop in June 2018 entitled "Changing Hearts and Minds: Improving Outcomes in Cancer Treatment-Related Cardiotoxicity" to highlight progress, ongoing work, and update scientific priorities since the 2013 Workshop. Here we will describe these advances and provide an overview of the research priorities identified. RECENT FINDINGS: Since 2013, the National Institutes of Health has increased its support of cancer treatment-related cardiotoxicity research through the funding of grants and coordination of internal and external working groups. Workshop participants identified knowledge gaps and recommended over 20 new promising opportunities in basic and clinical cardiotoxicity research. Significant progress on mechanisms, detection, management, and prevention of cardiotoxicity has been made over the past 5 years, yet some critical gaps remain.